Table 2.

Study Expectations and Previous HIV Cure-Related Research Experiences Among AIDS Clinical Trials Group A5345 Cohort A Respondents, by Intensively Monitored Antiretroviral Pause Status, n = 32

Question Pre-IMAP, n = 16 Post-IMAP, n = 16	Yes n (%)	No n (%)	Don't know n (%)	Missing n (%)	p valuea
Are you generally interested in HIV cure research?
Pre-IMAP	16 (100%)	0 (0%)	0 (0%)	0 (0%)	N/A
Post-IMAP	16 (100%)	0 (0%)	0 (0%)	0 (0%)
Have you previously participated in an HIV treatment study?
Pre-IMAP	8 (50%)	6 (38%)	2 (13%)	0 (0%)	.882
Post-IMAP	6 (38%)	8 (50%)	2 (13%)	0 (0%)
Have you previously participated in an HIV cure study?
Pre-IMAP	5 (31%)	9 (56%)	2 (13%)	0 (0%)	.272
Post-IMAP	10 (63%)	5 (31%)	1 (6%)	0 (0%)
Have you previously participated in a study that involved pausing your anti-HIV medications?
Pre-IMAP	1 (6%)	15 (94%)	0 (0%)	0 (0%)	1.000
Post-IMAP	1 (6%)	15 (94%)	0 (0%)	0 (0%)
Were you satisfied with the informed consent process?
Pre-IMAP	15 (94%)	0 (0%)	0 (0%)	1 (6%)	1.000
Post-IMAP	15 (94%)	1 (6%)	0 (0%)	0 (0%)
Are there any risks to you from participating in this study?
Pre-IMAP	13 (81%)	2 (13%)	1 (6%)	0 (0%)	1.000
Post-IMAP	13 (81%)	3 (19%)	0 (0%)	0 (0%)
Do you have any concerns about HIV inside your body increasing if you stop your anti-HIV medications?
Pre-IMAP	4 (25%)	11 (69%)	1 (6%)	0 (0%)	.357
Post-IMAP	8 (50%)	7 (44%)	1 (6%)	0 (0%)
Are there any direct benefits to you from participating in this study?
Pre-IMAP	8 (50%)	6 (38%)	2 (13%)	0 (0%)	.408
Post-IMAP	11 (69%)	5 (31%)	0 (0%)	0 (0%)
Will you receive a health benefit from being in this study?
Pre-IMAP	6 (38%)	6 (38%)	4 (25%)	0 (0%)	.035
Post-IMAP	1 (6%)	13 (81%)	2 (13%)	0 (0%)

Pre- and post-IMAP groups are independent samples.

^aFisher's exact test p-value (missing excluded).

IMAP, intensively monitored antiretroviral pause; N/A, not applicable.